Roshan K Topno |
|
|
|
Indian Council of Medical Research
·
Division of Epidemiology (Rajendra Memorial Research Institute of Medical Sciences)
|
Publications (13) View all
-
Article: Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India.
Roshan K Topno, Vidya N R Das, Alok Ranjan, Krishna Pandey, Dharmender Singh, Nawin Kumar, Niyamat A Siddiqui, Vijay P Singh, Shreekant Kesari, Narendra Kumar, Sanjeev Bimal, Annadurai Jeya Kumar, Chetram Meena, Ranjeet Kumar, Pradeep Das[show abstract] [hide abstract]
ABSTRACT: A prospective study was carried out in a cohort of 355 persons in a leishmaniasis-endemic village of the Patna District in Bihar, India, to determine the prevalence of asymptomatic persons and rate of progression to symptomatic visceral leishmaniasis (VL) cases. At baseline screening, 50 persons were positive for leishmaniasis by any of the three tests (rK39 strip test, direct agglutination test, and polymerase chain reaction) used. Point prevalence of asymptomatic VL was 110 per 1,000 persons and the rate of progression to symptomatic cases was 17.85 per 1,000 person-months. The incidence rate ratio of progression to symptomatic case was 3.36 (95% confidence interval [CI] = 0.75-15.01, P = 0.09) among case-contacts of VL compared with neighbors. High prevalence of asymptomatic persons and clinical VL cases and high density of Phlebotomus argentipes sand flies can lead to transmission of VL in VL-endemic areas.The American journal of tropical medicine and hygiene 09/2010; 83(3):502-6. · 2.59 Impact Factor -
Article: Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India.
Vijay P Singh, Alok Ranjan, Roshan K Topno, Rakesh B Verma, Niyamat A Siddique, Vidya N Ravidas, Narendra Kumar, Krishna Pandey, Pradeep Das[show abstract] [hide abstract]
ABSTRACT: We estimated the level of under-reporting of visceral leishmaniasis (VL) cases by comparing the actual reported cases with those expected as estimated using age- and sex-stratified incidence proportions obtained in a cohort of 31,324 persons. The average incidence proportion of VL cases in study population was 5.7/1,000 (95% confidence interval [CI] = 4.88-6.54) and 1.09/1,000 persons (95% CI = 0.99-1.20) based on the reported cases in two primary health centers. The overall magnitude of VL cases not reported to the government agencies was higher by a factor 4.17 (95% CI = 3.75-4.63) than for reported cases. The levels of under-reporting were 4.74 (95% CI = 4.11-5.47) in males and 3.51 (95% CI = 2.99-4.11) in females with no significant difference (P > 0.05). It was significantly higher in persons >or= 30 years of age than in persons 30 years of age (P < 0.05).The American journal of tropical medicine and hygiene 01/2010; 82(1):9-11. · 2.59 Impact Factor -
Article: Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Vidya Nand Rabi Das, Krishna Pandey, Neena Verma, Chandra Shekhar Lal, Sanjeev Bimal, Roshan Kamal Topno, Dharmendra Singh, Niyamat Ali Siddiqui, Rakesh Bihari Verma, Pradeep Das[show abstract] [hide abstract]
ABSTRACT: We report two cases of post-kala-azar dermal leishmaniasis (PKDL), which had subsequently developed after successful treatment of visceral leishmaniasis with miltefosine. Both patients had maculo-nodular lesions all over the body, and they were diagnosed as PKDL by parasitologic examination for Leishmania donovani bodies in a skin snip of lesions. Patients were put on amphotericin B and responded very well for nodular lesions with one course of treatment. However, longer duration of the treatment is needed for total clearance of macular lesions from body surface in PKDL cases. This is the first case report of PKDL in India, which developed after successful treatment of visceral leishmaniasis with miltefosine.The American journal of tropical medicine and hygiene 04/2009; 80(3):336-8. · 2.59 Impact Factor -
Article: Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples.
[show abstract] [hide abstract]
ABSTRACT: Visceral Leishmaniasis (VL) is a major public health problem of the eastern states in India namely Bihar, West Bengal, Jharkhand, and Eastern Uttar Pradesh. ...Journal of clinical microbiology 07/2009; 47(8):2684-5. · 4.16 Impact Factor -
SourceAvailable from: PubMed Central
Article: A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India.
Vidya Nand Rabi Das, Niyamat Ali Siddiqui, Krishna Pandey, Vijay Pratap Singh, Roshan K Topno, Dharmendra Singh, Rakesh Bihari Verma, Alok Ranjan, Prabhat Kumar Sinha, Pradeep Das[show abstract] [hide abstract]
ABSTRACT: There is significant variation in Amphotericin B (AMB) efficacy and relapses in antimony unresponsive visceral leishmaniasis (VL) cases over a period of time (10-15 years). Keeping in mind the above mentioned view this study was undertaken with an objective to assess the magnitude of cure and relapse rates of AMB in the treatment of antimony unresponsive VL cases. In a controlled, randomized nonblinded clinical trial, we evaluated the cure and relapse rate of Amphotericin B deoxycholate as compared to pentamidine. A total of 82 sodium stibogluconate (SSG) unresponsive and parasitologically confirmed VL cases were included in this study and randomized into two groups, test (Amphotericin B) and control (Pentamidine). Both the groups were treated with recommended dosages (as per World Health Organization guidelines) of respective medicines. All the patients were followed up on 1st, 2nd, and 6th month after end of treatment. Apparent cure rate in the Amphotericin B group was found to be 95% (39/41) compared with 83% (34/41) in the Pentamidine group, which shows significant statistical difference (p = 0.05). The ultimate cure rate was found 92% (38/41) in the Amphotericin B group compared to 73% (30/41) in the Pentamidine group, which shows a significant statistical difference (Yates corrected chi-square = 4.42, p = 0.04). Similarly, significant statistical difference was observed in the relapse rate of the Amphotericin group compared to the Pentamidine group (p = 0.03). AMB may still be the drug of choice in the management of resistant VL cases in Bihar, India. This is due to its consistent apparent cure rate (95%), low relapse rate (2.5%), and cost effectiveness compared with other available antileishmanial drugs. It is a safe drug even in case of pregnancy. Efforts should be taken to form a future strategy so that this drug and coming newer drugs do not meet a similar fate as has happened to SSG and pentamidine over a span of 10-15 years.Therapeutics and Clinical Risk Management 03/2009; 5(1):117-24.